Topp MS, Kufer P, Gökbuget N, et al.: Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. In: J Clin Oncol. 29. Jahrgang, 2011, S.2493–2498, doi:10.1200/JCO.2010.32.7270, PMID 21576633 (englisch).
Bargou R, Leo E, Zugmaier G, et al.: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. In: Science. 321. Jahrgang, Nr.5891, August 2008, S.974–7, doi:10.1126/science.1158545, PMID 18703743 (englisch).
Topp MS, Kufer P, Gökbuget N, et al.: Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. In: J Clin Oncol. 29. Jahrgang, 2011, S.2493–2498, doi:10.1200/JCO.2010.32.7270, PMID 21576633 (englisch).
Bargou R, Leo E, Zugmaier G, et al.: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. In: Science. 321. Jahrgang, Nr.5891, August 2008, S.974–7, doi:10.1126/science.1158545, PMID 18703743 (englisch).